nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Bacterial therapy for irritable bowel syndrome
|
Talley, Nicholas J |
|
|
5 |
7 |
p. 627-629 |
artikel |
2 |
British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis
|
Powell, Nick |
|
|
5 |
7 |
p. 679-697 |
artikel |
3 |
Converging pandemics: implications of COVID-19 for the viral hepatitis response in sub-Saharan Africa
|
Gupta, Neil |
|
|
5 |
7 |
p. 634-636 |
artikel |
4 |
Correction to Lancet Gastroenterol Hepatol 2020; 5: 425–27
|
|
|
|
5 |
7 |
p. e6 |
artikel |
5 |
Correction to Lancet Gastroenterol Hepatol 2020; 5: 649–57
|
|
|
|
5 |
7 |
p. e6 |
artikel |
6 |
Correction to Lancet Gastroenterol Hepatol 2020; 5: 667–68
|
|
|
|
5 |
7 |
p. e6 |
artikel |
7 |
Could a kiwifruit a day keep the doctor away?
|
Dimidi, Eirini |
|
|
5 |
7 |
p. 648 |
artikel |
8 |
Determining risk factors for mortality in liver transplant patients with COVID-19
|
Webb, Gwilym J |
|
|
5 |
7 |
p. 643-644 |
artikel |
9 |
Drinking alone: COVID-19, lockdown, and alcohol-related harm
|
The Lancet Gastroenterology & Hepatology, |
|
|
5 |
7 |
p. 625 |
artikel |
10 |
Early detection of pancreatic cancer
|
Pereira, Stephen P |
|
|
5 |
7 |
p. 698-710 |
artikel |
11 |
Green endoscopy: a call for sustainability in the midst of COVID-19
|
Maurice, James B |
|
|
5 |
7 |
p. 636-638 |
artikel |
12 |
Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial
|
Andresen, Viola |
|
|
5 |
7 |
p. 658-666 |
artikel |
13 |
Implications of gastrointestinal manifestations of COVID-19
|
Yang, Lijing |
|
|
5 |
7 |
p. 629-630 |
artikel |
14 |
Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis
|
Mao, Ren |
|
|
5 |
7 |
p. 667-678 |
artikel |
15 |
Patterns of care for inflammatory bowel disease in China during the COVID-19 pandemic
|
Chen, Yan |
|
|
5 |
7 |
p. 632-634 |
artikel |
16 |
Prevention of COVID-19 in patients with IBD
|
Segal, Jonathan P |
|
|
5 |
7 |
p. 639-640 |
artikel |
17 |
Prevention of COVID-19 in patients with IBD – Authors' reply
|
Ding, Nik Sheng |
|
|
5 |
7 |
p. 640-641 |
artikel |
18 |
Probiotics and COVID-19: one size does not fit all
|
Mak, Joyce W Y |
|
|
5 |
7 |
p. 644-645 |
artikel |
19 |
Protecting patients with IBD during the COVID-19 pandemic
|
Fiorino, Gionata |
|
|
5 |
7 |
p. 639 |
artikel |
20 |
Research in brief
|
Baker, Holly |
|
|
5 |
7 |
p. 647 |
artikel |
21 |
Resumption of daily services in a gastroenterology department in Guangzhou, China, in the wake of COVID-19
|
Han, Jing |
|
|
5 |
7 |
p. 645-646 |
artikel |
22 |
Screening FMT donors during the COVID-19 pandemic: a protocol for stool SARS-CoV-2 viral quantification
|
Ng, Siew C |
|
|
5 |
7 |
p. 642-643 |
artikel |
23 |
Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study
|
Feld, Jordan J |
|
|
5 |
7 |
p. 649-657 |
artikel |
24 |
Shortening treatment with direct-acting antivirals in HCV-positive organ transplantation
|
Holmes, Jacinta A |
|
|
5 |
7 |
p. 626-627 |
artikel |
25 |
Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey
|
D'Amico, Ferdinando |
|
|
5 |
7 |
p. 631-632 |
artikel |
26 |
Wastewater monitoring of SARS-CoV-2: lessons from illicit drug policy
|
Lancaster, Kari |
|
|
5 |
7 |
p. 641-642 |
artikel |